Christopher Rovaldi
Chief Operating Officer bij KEROS THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Christopher Rovaldi is SVP-Program Management & Operations bij Acceleron Pharma, Inc. De heer Rovaldi was eerder Director-Project Management bij Idenix Pharmaceuticals LLC, Senior Research Associate bij Periodontix, Inc. en Director-Project Management bij Cubist Pharmaceuticals LLC. Hij is afgestudeerd aan de University of New Hampshire en heeft daar ook een bachelor-diploma behaald.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KEROS THERAPEUTICS, INC.
-.--% | 13-02-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Christopher Rovaldi
| Bedrijven | Functie | Begin |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Chief Operating Officer | 01-02-2022 |
NS Pharma, Inc.
 NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ. | President | 01-05-2019 |
Eerdere bekende functies van Christopher Rovaldi
| Bedrijven | Functie | Einde |
|---|---|---|
| ACCELERON PHARMA INC. | Chief Operating Officer | 01-05-2018 |
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01-01-2007 |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01-01-2004 |
Periodontix, Inc.
 Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Corporate Officer/Principal | - |
Opleiding van Christopher Rovaldi
| University of New Hampshire | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KEROS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Commercial Services |
NS Pharma, Inc.
NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ. | Health Technology |
